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such as, musculoskeletal pain in tendons and joints (10).
Chitin is a natural polymer found in the exoskeleton of crustaceans 
and insects as well as in the cell walls of certain fungi (11). 
Chitosan, produced by the deacetylation of chitin, is a nontoxic 
biopolymer with versatile chemical and physical properties, but 
with poor solubility (12). Chitooligosaccharides (COS) are the 
hydrolyzed products of chitosan that is to have biocompatibility 
and biodegradability with greater solubility in water. COS has 
several bioactive applications in medicine, dentistry, as well as 
in the pharmaceutical, cosmetic and food industries (13). COS 
of low molecular weight are highly soluble and non-toxic in 
nature (14). COS has shown different antimicrobial, anticancer, 
antioxidant, angiotensin-converting enzyme inhibitory and 
immune stimulant effects (14, 15-19). 
The inhibitory effect of COS on acetylcholine esterase is of 
significant importance to the development of drugs from marine 
sources, for application in brain related diseases (20). On the 
basis of developing AChE inhibitors it became interesting to 
chemically modify the structural properties of chitosan and COSs 
in the search for novel treatment for AD and other diseases. In the 
present study, COS derivatives with different substitution groups 
such as aminoethyl-COS (AE-COS), diethylaminoethyl (DEAE-
COS), and dimethylaminoethyl (DMAE-COS) were studied to 
evaluate their effectiveness in the inhibition of BACE 1. 
MATERIALS AND METHODS
Preparation of COS
Chitooligosaccharides (MW 3-8 kDa) of 90 percent degree of 
deacetylation (DD) prepared from crab shells were donated by 
Kitto Life Co. (Seoul, Korea). 2-chloroethylamino hydrochloride 
(Fluka, Buchs, Switzerland), 2-dimethylamino-ethylchloride 
hydrochloride and 2-diethyl amino-ethylchloride hydrochloride 
(Sigma, St. Louis, MO) were used for chemical substitution 
reaction. In addition, BACE 1 (recombinant human BACE 1) assay 
kit was purchased from Pan Vera, USA and all other chemicals 
used were of high-grade. 
Synthesis of COS derivatives
COS derivatives were synthesized based on a previous protocol 
(19, 20) and described in Scheme 1. COS (500 mg) was 
dissolved in 20 ml (each) of 3 M aqueous substitution solution: 
2-chlorethylamino hydrochloride, 2-diethylamino-ethylchloride 
hydrochloride and 2-dimethylamino-ethylchloride hydrochloride 
at 40°C, which yielded AE-COS, DEAE-COS and DMAE-COS 
respectively. In addition, 20 ml NaOH (3M) was added drop wise 
to the reaction mixture and stirred for 48 h continuously. 
INTRODUCTION
Alzheimer’s disease (AD) is a progressive and ultimately fatal neurodegenerative disorder, afflicting approximately 40 percent of the population over 80 years of age. 
There are around 30 million people worldwide (1, 2). By 2010, it 
is estimated that there will be half a million AD sufferers in the 
United Kingdom (3). Currently, there are approximately 600 
million persons aged 60 years and older and this number will 
reach close to 2 billion in 2050 (4). Mechanistically speaking, AD 
is characterized by the accumulation of amyloid plaques and 
neurofibrillary tangles in the brain. The central etiology factor of 
AD is the amyloid beta (Abeta) peptide-mediated toxic amyloid 
plaque formation, which is generated by proteolytic processing 
of the amyloid precursor protein (APP) by beta-secretase (BACE-
1) and gamma-secretase. The transmembrane protein, Presenilin 
1 (PS1) plays a key role in the gamma-secretase dependent 
processing of APP to generate the beta-amyloid peptide, which 
leads to the pathogenesis of Alzheimer’s disease (5). A series of 
dual inhibitors of acetylcholinesterase (AChE) and β-secretase 
(BACE-1) have been studied to explore effective novel drugs for 
the treatment of AD (6). Though the treatment of AD is possible 
through the inhibition of the enzyme, acetylcholinesterase 
(AChE), preventing beta-amyloidosis by inhibiting the β-secretase 
enzyme is a prime target for the development of novel drugs (7). 
Therefore, inhibition of BACE-1, the rate-limiting enzyme in the 
production of Abeta, is an attractive therapeutic approach and 
many biopharmaceutical companies are currently working to 
discover new BACE 1 inhibitors for the treatment of AD (8, 9). At 
present, several BACE 1 inhibitors are under clinical trial. These 
include synthetic peptides, chemically modified tetracyclines, 
bisphosphonates compounds isolated from natural sources. 
However, most of these drugs are reported to exert side effects 
Different chemically substituted
chitooligosaccharides 
inhibit β-secretase activity
A. B. Ali Ahmed
A. BAKRUDEEN ALI AHMED1,2*, N.Y. YOON1, ROSNA MAT TAHA2, S.K. KIM1 
*Corresponding author
1. Pukyong National University Marine Bioprocess Research Center Busan, South Korea
2. University of Malaya, Institute of Biological Sciences, Faculty of Science, Kuala Lumpur, 50603, Malaysia
ABSTRACT
Chitooligosaccharide or COS is a kind of oligosaccharide that 
is an integral part of the nervous system. COS is synthesized 
by chemical substitution and derived AE-COS, DEAE-COS 
and DMAE-COS that are being shown on IC50 value. AE-COS 
and DMAE-COS exhibited four fold less inhibition than DEAE-
COS. In addition, non-competitive inhibitor was identified via 
a Dixon plot and the Ki inhibition constant (100 μg/mL).
We declared, chemical substitution of COS is a water soluble 
human safe BACE-1 inhibitor. 
Peer-reviewed ● Scientific article
DRUG DEVELOPMENT
78
chimica oggi/Chemistry Today - vol. 29 n. 5  September/October 2011
This solution was filtered, acidified (0.1 N HCl) and dialyzed against 
water for 2 days. The derivatives (AE-COS, DEAE-COS and DMAE-
COS) were freeze-dried and stored until used in the subsequent 
experiment with BACE enzyme (Figure 1). 
Enzyme assays
BACE1 assay was carried out according to the manual supplied 
with slight modifications (21). Briefly, a mixture of 10 µL of an 
assay buffer (50 mM sodium acetate, pH 4.5), 10 µL of BACE1 
(1.0 U/mL), 10 µL of the substrate (750 nM Rh-EVNLDAEFK-
Quencher in 50 mM ammonium bicarbonate), and 10 µL of a 
sample dissolved in the assay buffer was incubated for 60 min at 
25°C under dark conditions. The mixture was allowed for excitation 
at 530 nm and the emitted light at 590 nm was collected. The 
inhibition ratio was obtained by the following equation: Inhibition 
(percent) = [1- {(S-S0 / C-C0)}] x 100, where C was the fluorescence 
of a control (enzyme, assay buffer, and substrate) after 60 min of 
incubation, C0 was the fluorescence of the control at time zero, 
S was the fluorescence of the test samples (enzyme, sample 
solution, and substrate) after 60 min of incubation, and S0 was 
the fluorescence of the tested samples at time zero. All data are 
the means of duplicated experiments. To check the quenching 
effect of the samples, the sample was added to the reaction 
mixture C, and any reduction in fluorescence by the sample was 
then calculated. 
Dixon plot analysis
Dixon plot analysis was performed as follows: BACE 1 substrate 
was divided into three concentration groups. The reaction 
velocity was measured at a fixed substrate concentration with 
different inhibitors. A graph of the 1/V (min/F.U) against the 
inhibitor concentration was plotted. A graphical method was 
determined, the type of enzyme inhibition and constant enzyme 
inhibitor complex (Ki). In addition, the enzyme rate (v) was 
determined at two or more substrate concentrations, and over 
a range of inhibitor concentrations (I). In a plot of 1/v against I, 
data for each substrate concentration fell on straight lines that 
intersected at 1 - Ki and the presentation of enzyme kinetic data 
by which a Michaelis constant, Km (Michaelis kinetics) on an 
inhibitor constant, Ki was determined.
RESULTS AND DISCUSSION
Chitooligosaccharide derivatives have bioactive properties, 
and their pro these properties differ depending on the chemical 
substitution (20). In the present study, we calculated the BACE 1 
inhibition by the differently chemically substituted AE-COS, DEAE-
COS and DMAE-COS derivatives. 
The COS derivatives were synthesized through the displacement 
of the functional groups. In addition, the hydroxyl groups of 
the pyranose ring were strongly reactive in their chemical 
reaction (22). From the above reactions, we have clearly 
seen that the hydroxyl group at the C-6 of the pyranose 
ring showed the highest reactivity and was replaced the 
AE, DEAE and DMAE groups, respectively (Scheme 1). 
The substituted group was identified by 1H NMR spectra (20). 
An inspection of the 1H NMR spectra of AE-COS demonstrated 
the presence of three functional proton signals for acetyl 
residue, -CH2N and pyranose unit at δ 2.9-3.6, respectively (18). 
Additionally, DMAE-COS showed peaks for the methyl and 
methylene proton groups at positions between δ 2.9 and 3.0. In 
the same fashion, DEAE-COS displayed signals for methyl and 
methylene protons at δ 1.3 and 3.3 as well as methyl protons of 
the protonated DEAE group between δ 1.5 and 1.6, respectively 
(Figure 2).
Marine drugs are a potential tool in the search for a cure 
for Alzheimer’s disease and could be rectify the blood brain 
barrier and the developed plasma membrane (23). Three 
COSs (AE-COSs, DEAE-COSs, DMAE-COSs) were shown in their 
different potential for BACE 1 inhibition with dose dependent 
Scheme 1. Synthesis of AE, DEAE and DMAE-Chitooligosaccharide.
Figure 1. Schematic diagram representation of 
chitooligosaccharides preparation and β-secretase inhibition assay.
Figure 2. 1H NMR spectrum (400 MHz) of COS derivatives in D2O.
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CONCLUSIONS
In this study, we synthesized novel COS derivatives with different 
chemical substitution groups and evaluated their BACE 1 
inhibitory activities. The results showed that DEAE-COSs prepared 
from chitooligosaccharides (MW 3-8 kDa) exhibited the highest 
BACE 1 inhibitory activity. In addition, the BACE 1 inhibition 
pattern of DEAE-COSs was found to be non-competitive, and the 
inhibition constant (Ki) was 100 μg/mL. This result suggests that the 
amino group plays an important role in BACE 1 inhibitory activity. 
In addition, the β-secretase inhibition is the most promising 
strategy for modifying the course of AD, and many companies 
have long been attempting to develop β-secretase inhibitors 
for this purpose. To develop medicines with sufficient clinical 
efficacy, the preclinical data must allow accurate prediction of 
the clinically effective dose. The progress in the knowledge base 
for β-secretase inhibitors appears to have reached a stage at 
which the ultimate emergence of β-secretase inhibitor drugs is 
probable.
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and percentage inhibition. The percentage inhibition could 
reach 69.2, 75.24, and 60.24 percent at the concentration of 
500 µg/mL respectively (Figure 3). Among them, DEAE-
COSs showed the strongest inhibitory potential compared 
to AE-COSs, and DMAE-COSs. We have reported that COS with 
antioxidant properties were synthesized from chitosan by hydrolysis 
in a dose-dependent manner (24). The importance of this approach 
is underscored by findings that human mutations at the P1 and 
P2 BACE 1 cleavage subsides result in early-onset familial AD (25). 
We also tested concentrations of the COS derivatives at above 
500 µg/mL and found that these higher concentrations 
significantly decreased the BACE 1 inhibition effectiveness. 
Figure 2 shows that AE-COSs and DMAE-COSs possess weak BACE 
1 inhibition compared to DEAE-COSs. At the concentration of 
625 µg/mL AE-COSs, DMAE-COSs, and DEAE-COSs recorded 43.6, 
61.5, and 38.2 percent inhibition of BACE 1 (data not shown). The 
IC50 values were calculated by non-linear regression and show 
the IC50 value of DEAE-COSs (4.32 μg/mL) is 4 times less inhibitory 
than AE-COSs (17.4 μg/mL) and DMAE-COSs (12.9 μg/mL) 
(Figure 3). 
Chemically substituted compounds inhibited BACE 1 in a dose-
dependent manner and were non-competitive with the substrate 
in the Dixon plots (Figure 3). 
The chemical modification chitooligosaccharides kinetic 
behaviour of the chemically modified COSs was determined by 
Dixon plot analysis under the fluorogenic substrate. 
In addition, the type of inhibition pattern is important to for 
understanding the mechanism of enzyme action and the inhibitor-
binding site. DEAE-COSs inhibition pattern was analyzed by Dixon 
plots (at three concentrations: 125 μg/mL; 250 μg/mL; 500 μg/mL). 
Therefore, DEAE-COSs formed the inhibitor complexes during the 
enzyme reaction to reduce the efficiency of catalysis.  The Ki 
value was calculated by the secondary plot of Line weaver-Burk, 
with the slopes of each line in the Lineweaver-Burk plot being 
plotted against different concentrations of DEAE-COSs, and the 
Ki value was determined to be 100 μg/mL. We also analyzed the 
kinetic behaviour using Dixon plots, and the results showed that 
DEAE-COSs acts as a competitive inhibitor (Figure 4). Thus, the 
isolated compounds appeared to be relatively specific inhibitors 
of BACE 1 as is the case of the other natural inhibitors we had 
isolated (25-26). 
The Ki value was directly measured for Dixon plot as an intercept 
on the x-axis. DEAE-COSs could be formed by the hydrogen 
bonding and /or the electrostatic interaction between the 
positively charged amide group at C-2 position and the 
carboxylates of the catalytic residues. 
There are reasons for DEAE-COSs having the more potent 
BACE 1 inhibition activity compared to AE-COSs and DMAE-COSs. 
However, more studies on the relationship between molecular 
size and inhibition activity are needed.
Figure 3. Concentration-dependent inhibition of β-secretase by 
chemical modification compounds (AE-COSs, DEAE-COSs,  
DMAE-COSs).
Figure 4. Determination of inhibition pattern of DEAE-
Chitooligosaccharides on BACE 1 using Dixon plots. Substrate 
concentration was --ο-- 125 μg/mL; --●-- 250 μg/mL; --▼-- 500 μg/mL.
